Litcius/Paper detail

Once-weekly semaglutide in people with HIV-associated lipohypertrophy: a randomised, double-blind, placebo-controlled phase 2b single-centre clinical trial

Allison Ross Eckard, Qian Wu, Abdus Sattar, Kianoush Ansari-Gilani, Danielle Labbato, Theresa Foster, Aaron A Fletcher, Ruth Adekunle, Grace A. McComsey

2024The Lancet Diabetes & Endocrinology39 citationsDOIOpen Access PDF

Topics & Concepts

MedicineSemaglutideDouble blindPlaceboHuman immunodeficiency virus (HIV)Clinical trialSingle blindRandomized controlled trialInternal medicinePhysical therapyDiabetes mellitusAlternative medicineType 2 diabetesFamily medicineEndocrinologyPathologyLiraglutideHIV-related health complications and treatmentsAdipokines, Inflammation, and Metabolic DiseasesDiabetes, Cardiovascular Risks, and Lipoproteins
Once-weekly semaglutide in people with HIV-associated lipohypertrophy: a randomised, double-blind, placebo-controlled phase 2b single-centre clinical trial | Litcius